André Dallmann

Dr. André Dallmann

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2020 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
JKJamil M. Kazma
Jamil M. Kazma
Johannes Van den AnkerJohannes Van den Anker
Johannes Van den Anker
Karel AllegaertKarel Allegaert
Karel Allegaert
ADAndré Dallmann
André Dallmann
HAHoma Ahmadzia
Homa Ahmadzia

11 April 2017 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
ADAndré Dallmann
André Dallmann
IIIbrahim Ince
Ibrahim Ince
MMMichaela Meyer
Michaela Meyer
SWStefan Willmann
Stefan Willmann
TEThomas Eissing
Thomas Eissing
GHGeorg Hempel
Georg Hempel

8 April 2017 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
ADAndré Dallmann
André Dallmann
IIIbrahim Ince
Ibrahim Ince
JSJuri Solodenko
Juri Solodenko
MMMichaela Meyer
Michaela Meyer
SWStefan Willmann
Stefan Willmann
GHGeorg Hempel
Georg Hempel

18 September 2017 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
ADAndré Dallmann
André Dallmann
IIIbrahim Ince
Ibrahim Ince
KCKatrin Coboeken
Katrin Coboeken
TEThomas Eissing
Thomas Eissing
GHGeorg Hempel
Georg Hempel

6 May 2018 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ADAndré Dallmann
André Dallmann
Marc PfisterMarc Pfister
Marc Pfister
JAJohn van Den Anker
John van Den Anker
TEThomas Eissing
Thomas Eissing

4 May 2021 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
PDF file
SFSebastian Frechen
Sebastian Frechen
JSJuri Solodenko
Juri Solodenko
TWThomas Wendl
Thomas Wendl
ADAndré Dallmann
André Dallmann
IIIbrahim Ince
Ibrahim Ince
RBRolf Burghaus
Rolf Burghaus
The success of applications of physiologically‐based pharmacokinetic (PBPK) modeling in drug development and drug labeling has triggered regulatory agencies to demand rigorous demonstration of the predictive capability of the specific PBPK platform for a particular intended application purpose. The effort needed to comply with such qualification requirements exceeds the costs for any individual PBPK application. Because changes or updates of a PBPK platform would require (re‐)qualification, a reliable and efficient generic qualification framework is needed. We describe the development and implementation of an agile and sustainable technical framework for automatic PBPK platform (re‐)qualification of PK‐Sim® embedded in the open source and open science GitHub landscape of Open Systems Pharmacology. The qualification approach enables the efficient assessment of all aspects relevant to the qualification of a particular purpose and provides transparency and traceability for all stakeholders. As a showcase example for the power and versatility of the qualification framework, we present the qualification of PK‐Sim® for the intended purpose of predicting cytochrome P450 3A4 (CYP3A4)–mediated drug–drug interactions (DDIs). Several perpetrator PBPK models featuring various degrees of CYP3A4 modulation and different types of mechanisms (competitive inhibition, mechanism‐based inactivation, and induction) were coupled with a set of PBPK models of sensitive CYP3A4 victim drugs. Simulations were compared to a comprehensive data set of 135 observations from published clinical DDI studies. The platform's overall predictive performance showed reasonable accuracy and precision (geometric mean fold error of 1.4 for both area under the plasma concentration‐time curve ratios and peak plasma concentration ratios with/without perpetrator) and suggests that PK‐Sim® can be applied to quantitatively assess CYP3A4‐mediated DDI in clinically untested scenarios.